Headquartered in Basel, Switzerland, Novartis was created in 1996 through the merger of two former Swiss giants in the pharmaceutical field, Ciba-Geigy and Sandoz. With more than 80 years of presence in the country, Novartis Mexico is today a 1,700-people organization with a turnover of USD 600 million in 2014, three production plants in the country and investing more than USD 2 million in R&D to support approximately 40 clinical trials which involve almost 28,000 Mexican patients.
Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing…
Novartis strives for “creating solutions for patients that go beyond the pill”. The country head and next president of CANIFARMA discusses how the company is using new programs and technology…
Nuclear medicine is not a concept we are familiar with. Could you give us a brief breakdown of what encompasses nuclear medicine? Nuclear medicine works the following way: a small…
Convatec acquired Boston Medical Device in September 2011. Which have been the major challenges following the acquisition, and which synergies are to be expected? The story of BMD would suffice…
Baxter established itself in Mexico as early as 1948 through the acquisition of a local manufacturer, Madom’s Pharmaceutical. In a vast market like France, operations started 40 years ago; in…
Hospira Mexico is not only the control centre for Central America and Caribbean operations, but it is the Latin American regional office. Why was such importance given to Mexico in…
Biofarma Natural CMD started operations in 1992 as a company focused on natural products. Please can you give us an insight into how the company has grown since then? I…
Carnot is celebrating 70 years as a company. There have been a lot of changes over this time, but more specifically over the last three to four years, please can…
We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in 1995. The…
Over ten years ago, the economic concept of the ‘BRIC’ countries- Brazil, Russia, India and China – was formed, and it’s pretty much all we’ve heard about ever since.…
Despite being in the Mexican market for over twenty years, biosimilars have never been regulated as a separate entity. They have always been regulated as simply another category of generic…
We read in an article by El Economista last year that you believe “there is no other company with such a diverse range of therapies as MSD and that makes…
See our Cookie Privacy Policy Here
